Abliva AB

Abliva – Delivering mitochondrial health
Abliva discovers and develops medicines for the treatment of mitochondrial diseases. These rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is in clinical trials. NV354, an energy replacement therapy, has completed preclinical development. Abliva is based in Lund, Sweden, and is since spring 2025 a member of Dutch Pharming Group N.V.